Trial Profile
EXTEND (Eltrombopag Extended Dosing Study): An Extension Study of Eltrombopag Olamine (SB-497115-GR) in Adults, With Idiopathic Thrombocytopenic Purpura (ITP), Previously Enrolled in an Eltrombopag Study
Status:
Completed
Phase of Trial:
Phase III
Latest Information Update: 29 Aug 2023
Price :
$35
*
At a glance
- Drugs Eltrombopag (Primary)
- Indications Idiopathic thrombocytopenic purpura; Idiopathic thrombocytopenic purpura
- Focus Adverse reactions
- Acronyms EXTEND
- Sponsors GlaxoSmithKline
- 04 Dec 2018 Results of post hoc analysis presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 17 Jun 2018 Results from the phase III Extend study and a phase IV study presented at the 23rd Congress of the European Haematology Association
- 17 Jun 2018 Results assessing hepatobiliary adverse events presented at the 23rd Congress of the European Haematology Association